“Too good to be true” clinic claim checker
A short checklist for working out whether a UK peptide or weight-management clinic claim is realistic. Use it before you book, before you pay, and before you accept a follow-up. If a claim fails two or more tests, walk away.
The eight tests
1. Is the prescriber named and findable?
A real UK prescriber is a named individual on the GMC, NMC, or GPhC register. If the clinic refuses to share the name, or says “our prescriber will contact you,’’ the claim fails. Anonymous prescribers don’t take clinical responsibility.
2. Is the dispensing pharmacy named and registered?
The pharmacy supplying any medicine should be on the GPhC (or PSNI) register. If the clinic uses “our partner pharmacy’’ without naming it, the claim fails.
3. Is the medicine a licensed UK brand?
For GLP-1s, the licensed UK products are Wegovy, Ozempic, Mounjaro, Saxenda, Rybelsus, Victoza, Trulicity, and Byetta/Bydureon. “Compounded semaglutide’’ and “tirzepatide-equivalent’’ are not licensed UK products. For other peptides, the question is even sharper — most don’t have UK licences at all.
4. Does the assessment actually assess?
A real clinical assessment for any prescription covers history, medications, contraindications, mental-health screen, and (often) baseline bloods. A 60-second online form asking for height, weight, and a credit card is not an assessment.
5. Is the outcome claim specific and time-bound?
“Lose 20kg in 12 weeks — guaranteed’’ is a per-se CAP code breach and a clinical impossibility to promise individually. Real outcomes vary; honest clinics quote ranges and acknowledge variability.
6. Is the safety profile being communicated?
Real GLP-1 clinics will mention nausea, the gallbladder signal, the pancreatitis red flags, and pregnancy contraindications. Marketing that promises results with no mention of side effects is filtering out the inconvenient half of the medicine.
7. Is the pricing in the genuine market range?
Significantly underpriced GLP-1 supply — especially during a known shortage — is a counterfeit-supply signal. Cheaper isn’t better when the price gap reflects skipped quality assurance.
8. Is follow-up part of the offer?
A one-off prescription with no follow-up isn’t responsible prescribing. Real clinics build in titration reviews, side-effect checks, and an adverse-event escalation path. No follow-up is the “sell-and-forget’’ model.
Common clinic claims and what they really mean
| The claim | What it usually means |
|---|---|
| “Doctor-prescribed” | Doesn’t mean the doctor assessed you. Could be a doctor approving lists of pre-filtered orders. |
| “UK-registered pharmacy” | Trust but verify. Look up the actual pharmacy name on the GPhC register. |
| “Compounded” | For GLP-1s, almost always outside the lawful UK ‘specials’ framework. |
| “Research-grade” | Unlicensed-medicine supply with no regulatory protection. |
| “Discreet packaging” | Consumer-supply language, not medical-supply language. |
| “No GP letter required” | True for lawful private routes; suspicious when paired with “no clinical assessment”. |
| “Guaranteed results” | CAP code breach. Honest clinics don’t guarantee. |
| “Same active ingredient at half the price” | The regulated supply chain costs the missing half. That’s where the safety lives. |
| “Limited stock — order now” | Urgency framing. Counterfeit-supply marketing pattern. |
| “As featured in [publication]” | Verify. Some claims are entirely fabricated. |
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Guaranteed 2 stone weight loss in 3 months”
Specific guaranteed outcome breaches CAP slimming rules and overstates what any clinician can promise an individual.
“Reverse Type 2 diabetes with our 12-week peptide programme”
‘Reverse diabetes’ is a medicinal claim. ‘Peptide programme’ implies a regimen no UK licensed product is sold as.
“Anti-ageing peptide therapy — clinically proven”
‘Clinically proven’ requires controlled trial evidence in humans for the marketed outcomes — which most ‘anti-ageing peptides’ don't have.
“Doctor-approved compounded semaglutide”
Doctor approval doesn't validate mass-market compounded GLP-1 supply outside the ‘specials’ framework.
“Free initial consultation — no obligation”
Often the consultation isn't a clinical assessment — it's a sales call.
Sources & further reading
- GPhC — Online registers — pharmacyregulation.org
- GMC — The Medical Register — gmc-uk.org
- ASA / CAP advertising codes — asa.org.uk
- ASA — make a complaint — asa.org.uk
- MHRA — gov.uk